Related Experiment Video
Updated: Jan 10, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients
Anna M Jermakowicz1, Luz Ruiz1, Jonathan Chu1
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Abstract:
Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates vary widely between subgroups, with an average overall survival of 70%. Recurrent medulloblastoma is highly aggressive, treatment-resistant, and usually fatal. In addition, current treatments are highly toxic to the developing brain and surviving patients suffer from lifelong side effects. Therefore, novel therapeutic options are urgently needed. To inform risk-based, personalized therapy, we developed a novel platform called DrugSeq, which allows predictions of drug sensitivities in patients across medulloblastoma subgroups. We used a perturbagen-response dataset to calculate transcriptional response signatures for each drug and compared this to patient medulloblastoma tumor gene expression. We then stratified patients by molecular subgroup and used an ANOVA analysis to identify drugs that selectively targeted each subgroup. We found distinct differences in transcriptional profiles and predicted drug sensitivity for each medulloblastoma subgroup. We identified kinase inhibitors, epigenetic inhibitors, and several drugs that have been investigated in drug repositioning studies for cancer. We posit that DrugSeq may identify novel therapies and facilitate patient stratification in clinical trials, leading to more successful targeted medulloblastoma therapies that improve tumor response while minimizing late toxicities. This computational tool can also be used for other cancers to stratify patients based on any clinical or molecular feature.
Insights
Novel DrugSeq platform predicts medulloblastoma drug sensitivities. It identifies targeted therapies for pediatric brain tumors, improving treatment and reducing side effects.
Area of Science:
- Oncology
- Genomics
- Computational Biology
Background:
- Medulloblastoma is the most common pediatric brain tumor, with survival rates varying by subgroup.
- Recurrent medulloblastoma is aggressive, treatment-resistant, and current therapies cause significant toxicity.
- Novel therapeutic strategies are essential for improved patient outcomes and reduced long-term side effects.
Purpose of the Study:
- To develop a computational platform, DrugSeq, for predicting drug sensitivities in medulloblastoma subgroups.
- To enable risk-based, personalized therapy by stratifying patients based on molecular features.
- To identify novel therapeutic options and facilitate clinical trial stratification for medulloblastoma.
Main Methods:
- Utilized a perturbagen-response dataset to generate drug transcriptional response signatures.
- Compared drug signatures with patient medulloblastoma tumor gene expression data.
- Employed ANOVA analysis to stratify patients by molecular subgroup and identify subgroup-selective drugs.
Main Results:
- Distinct differences in transcriptional profiles and predicted drug sensitivities were observed across medulloblastoma subgroups.
- Identified potential therapeutic agents including kinase inhibitors and epigenetic inhibitors.
- Found several drugs suitable for repositioning studies in medulloblastoma treatment.
Conclusions:
- DrugSeq platform effectively predicts medulloblastoma drug sensitivities and facilitates patient stratification.
- Identified targeted therapies may improve tumor response and minimize late toxicities in pediatric brain tumors.
- The DrugSeq computational tool has broader applicability for patient stratification in other cancers.
More Related Videos
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
